Skip to content
10-Q

Quarterly Report

Aegerion Pharmaceuticals, Inc.

0001628280-16-020875

← back to feed
Filed
Nov 4, 2016 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2016 · Oct 31, 2016 29.55M sh
Capex Q3 2016 · Sep 30, 2016 $1.54M
Capex Q3 2016 · Sep 30, 2015 $1.21M
Short Term Debt Q3 2016 · Sep 30, 2016 $2.92M
Short Term Debt Q3 2016 · Dec 31, 2015 $0
Cash And Equivalents Q3 2016 · Sep 30, 2016 $32.36M
Cash And Equivalents Q3 2016 · Dec 31, 2015 $64.5M
Cash And Equivalents Q3 2016 · Sep 30, 2015 $71.74M
Cash And Equivalents Q3 2016 · Dec 31, 2014 $375.94M
Stockholders Equity Q3 2016 · Sep 30, 2016 −$12.83M
Stockholders Equity Q3 2016 · Dec 31, 2015 $115.55M
Current Liabilities Q3 2016 · Sep 30, 2016 $118.79M
Current Liabilities Q3 2016 · Dec 31, 2015 $86.89M
Total Liabilities Q3 2016 · Sep 30, 2016 $366.65M
Total Liabilities Q3 2016 · Dec 31, 2015 $318.65M
Current Assets Q3 2016 · Sep 30, 2016 $120.78M
Current Assets Q3 2016 · Dec 31, 2015 $175.94M
Total Assets Q3 2016 · Sep 30, 2016 $353.83M
Total Assets Q3 2016 · Dec 31, 2015 $434.2M
Sga Expense Q3 2016 · Sep 30, 2016 $27.83M
Sga Expense Q3 2016 · Sep 30, 2016 $107.94M
Sga Expense Q3 2016 · Sep 30, 2015 $43.92M
Sga Expense Q3 2016 · Sep 30, 2015 $133.52M
Rd Expense Q3 2016 · Sep 30, 2016 $9.94M
Rd Expense Q3 2016 · Sep 30, 2016 $30.5M
Rd Expense Q3 2016 · Sep 30, 2015 $11.28M
Rd Expense Q3 2016 · Sep 30, 2015 $33.55M
Net Income Q3 2016 · Sep 30, 2016 −$26.57M
Net Income Q3 2016 · Sep 30, 2016 −$138.93M
Net Income Q3 2016 · Sep 30, 2015 −$9.77M
Net Income Q3 2016 · Sep 30, 2015 −$36.74M
Operating Income Q3 2016 · Sep 30, 2016 −$18.77M
Operating Income Q3 2016 · Sep 30, 2016 −$116.95M
Operating Income Q3 2016 · Sep 30, 2015 −$2.39M
Operating Income Q3 2016 · Sep 30, 2015 −$16.51M
Cost Of Revenue Q3 2016 · Sep 30, 2016 $13.84M
Cost Of Revenue Q3 2016 · Sep 30, 2016 $51.87M
Cost Of Revenue Q3 2016 · Sep 30, 2015 $14.49M
Cost Of Revenue Q3 2016 · Sep 30, 2015 $40.32M